Navigation Links
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

VIENNA, Oct. 21 /PRNewswire/ -- Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

Intercell's vaccine candidate has demonstrated a sustained reduction of viral load in chronic Hepatitis C (CHC) patients in a Phase II proof-of-concept trial. Nitazoxanide is an oral therapy that targets host cell factors involved in HCV replication and is not associated with viral mutations conferring resistance. Nitazoxanide has been shown to induce sustained virologic response as monotherapy in some patients chronically infected with HCV.

The planned European Phase II trial will include about 60 treatment-naïve patients chronically infected with HCV genotype-1 in three treatment arms: (1) IC41 plus nitazoxanide, (2) IC41 plus nitazoxanide and Pegasys® (peginterferon alfa-2a) and (3) Pegasys and Copegus® (ribavirin), the current standard of care, as an active control. The primary endpoint will be sustained virologic response (no detectable HCV RNA 24 weeks after end-of-treatment).

The companies involved in the combination study will retain commercial rights for their respective products.

"We are very pleased about this important next step in the development of our vaccine candidate against Hepatitis C. The distinctly different mode-of-action and the outstanding tolerability of both treatments create a joint approach in a field that will continue to have high unmet medical need over the next decades," stated Gerd Zettlmeissl, CEO of Intercell.

"We are excited about this novel therapeutic approach for chronic Hepatitis C," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark. "There is an important need for novel therapies that offer improvements in safety and efficacy com
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
2. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
3. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
4. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
8. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
11. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Officer, will present at the Stem Cell Meeting on ... 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... 2014 STUDY OBJECTIVES The objective ... provide an overview of the current and future ... The key objective is to present a comprehensive ... an important tool in the treatment of various ... strategies within the protein therapeutics market, which includes ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
... HIGHLIGHTS:2011 Results (all percentages are to comparable periods ... increased 11% to $626 million. Q3 sales grew organically by ... organically by 4% and 2%, respectively.  Recently completed acquisitions contributed ... contributed an additional 5% to reported sales growth in Q3. ...
... Oct. 25, 2011 Abbott (NYSE: ABT ... – one undergraduate and one graduate – living with ... Undergraduate Student Scholarship, and Emily Kramer-Golinkoff, winner of the ... with CF who were eligible to receive the two ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Abbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees 2Abbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees 3
(Date:10/1/2014)... and Physical Sciences Research Council (EPSRC) will focus ... control systems which run, for example, manufacturing plants, ... network. , The research will help understand ... the systems behind our critical national infrastructure. ... Systems (RITICS), based at Imperial College London, is ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining ... , Senior citizens can purchase a joint life insurance ... A joint policy is cheaper, but will only pay ... Life insurance can be used to cover important funeral ... online, as the application process is simple and straightforward. ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater ... of choice, is announcing a discounted cost on Botox ... , “We’re doing this because we want to give ... skin clinic in Toronto,” says Dr. Brian Sieber, founder ... Anti Aging Clinic, including laser facials, genesis laser facials, ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... diets are of no use in losing weights and are ... from the American Dietetic Association//. Dieticians consulted by WebMD also ... gym is no answer either. ,The growing rate of ... who are particularly alarmed at the increasing childhood obesity. Cynthia ...
... a Cesarean operation to deliver Japan's male heir. The ... doctor of the Imperial Household agency//. ,he ... the placenta, a condition called as placenta previa. "We ... operation. It is also highly possible that the delivery ...
... pay compensation and apologise to a young woman orphaned by ... ,Beijing Chaoyang District Court ordered the local China Times ... and issue an apology on its front page for a ... of the woman and the story of her sufferings after ...
... the treatment of recurrent ovarian cancer ignoring the advice of ... in combination with carboplatin (chemotherapy) is very effective for women ... by its generic name gemcitabine and was approved after the ... the statistics of the American Cancer Society about 22,000 women ...
... be mandatory on all tobacco products soon failing which ... ,Other health warnings that could appear on ... pictorial representation of ill-effects of tobacco use and a ... headed by Anbumani Ramadoss, who has been a staunch ...
... than half of human cancers involve mutations in the ... the normal p53 protein in defending// against cancer. Similarly, ... protein occur in its DNA-binding core domain, pointing to ... to its anti-cancer activity. ,Clearly, a detailed ...
Cached Medicine News:Health News:DNA-bound p53 Tumor Suppressor Protein Structure Determined 2
Jewelers bipolar forceps, 10 cm....
European bipolar foot activated forceps....
Straight, blunt and pointed tips....
Cushing bayonet....
Medicine Products: